1. Home
  2. SMID vs HURA Comparison

SMID vs HURA Comparison

Compare SMID & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smith-Midland Corporation

SMID

Smith-Midland Corporation

HOLD

Current Price

$30.83

Market Cap

156.3M

Sector

Industrials

ML Signal

HOLD

Logo TuHURA Biosciences Inc.

HURA

TuHURA Biosciences Inc.

HOLD

Current Price

$1.96

Market Cap

144.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMID
HURA
Founded
1960
2009
Country
United States
United States
Employees
N/A
22
Industry
Building Materials
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
156.3M
144.3M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
SMID
HURA
Price
$30.83
$1.96
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$9.50
AVG Volume (30 Days)
5.9K
466.3K
Earning Date
04-14-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
62.76
N/A
EPS
2.36
N/A
Revenue
$93,446,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.06
N/A
Revenue Growth
19.03
N/A
52 Week Low
$25.60
$0.41
52 Week High
$43.62
$3.90

Technical Indicators

Market Signals
Indicator
SMID
HURA
Relative Strength Index (RSI) 47.93 37.34
Support Level $26.74 $1.66
Resistance Level $36.74 $2.20
Average True Range (ATR) 1.52 0.20
MACD 0.03 -0.05
Stochastic Oscillator 56.61 7.22

Price Performance

Historical Comparison
SMID
HURA

About SMID Smith-Midland Corporation

Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.

About HURA TuHURA Biosciences Inc.

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Share on Social Networks: